22nd week of 2009 patent applcation highlights part 45 |
Patent application number | Title | Published |
20090137595 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF - The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. | 2009-05-28 |
20090137596 | G-PROTEIN INHIBITOR - A subject of the invention is a product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent for a therapeutic use which is simultaneous, separate or spread over time in the treatment of cancer. | 2009-05-28 |
20090137597 | Novel quinoxalinone derivatives - A quinoxalinone derivative of the formula (I): | 2009-05-28 |
20090137598 | METHOD OF TREATING METABOLIC DISORDERS AND DEPRESSION WITH DOPAMINE RECEPTOR AGONISTS - This invention relates to methods and formulations for treating metabolic disorders and depression. In some embodiments, the methods comprise administering a dopamine receptor agonist and an anti-depressant. | 2009-05-28 |
20090137599 | Methods of identifying responders to dopamine agonist therapy - The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein one or more of: (a) NE metabolites, (b) NE/NE metabolites:dopamine/dopamine metabolites, (c) NE and serotonin, (d) NE/NE metabolites and serotonin, (e) NE and serotonin metabolites, (f) NE/NE metabolites and serotonin metabolites, or (g) NE is/are greater than about 30% over normal level; or dopamine/dopamine metabolites are less than about 30% below normal; or fasting triglycerides are greater than about 150 mg/dl and/or said patient has blood pressure of greater than about 135/85 mm Hg. The present invention is also directed to treating identified patients with dopamine agonist therapy. | 2009-05-28 |
20090137600 | Antiplatelet agent and process for producing the same - A compound having an action of suppressing platelet aggregation is provided. This compound also exhibits excellent physical properties and oral absorbability. This compound is represented by formula (Ib): Its production method is also provided. | 2009-05-28 |
20090137601 | L-Phenylalanine Derivatives - The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins. | 2009-05-28 |
20090137602 | Combination preparation against vertigo - The use of cinnarizine and dimenhydrinate or their physiologically compatible salts in combination is described for the treatment of vertigo of any genesis. | 2009-05-28 |
20090137603 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF - The present invention provides a novel amide compound represented by the following formula, which has a matrix metalloproteinase inhibitory activity and is useful as a pharmaceutical agent. | 2009-05-28 |
20090137604 | TRI-HETEROCYCLIC COMPOUNDS AND A PHARMACEUTICAL COMPRISING THEM AS AN ACTIVE INGREDIENT - Tri-heterocyclic compound of formula (I) | 2009-05-28 |
20090137605 | POLYMORPHIC FORMS OF ZIPRASIDONEAND ITS HYDROCHLORIDE SALT AND PROCESS FOR PREPARATION THEREOF - The present invention is related to crystalline forms of ziprasidone and its hydrochloride salt and an amorphous form of ziprasidone hydrochloride and the process for the preparation thereof. The crystalline forms and amorphous form of the invention are suitable for pharmaceutical purposes in the treatment of psychosis. The processes of the invention are simple, non-hazardous and commercially suitable. | 2009-05-28 |
20090137606 | Chewable formulations - The invention encompasses a solid dose pharmaceutical composition comprising a disagreeable-tasting drug and processes for preparation of the pharmaceutical composition. The pharmaceutical composition is designed not to be swallowed immediately. | 2009-05-28 |
20090137607 | FUSED BICYCLIC PYRIMIDINES - Compounds of formula (I) | 2009-05-28 |
20090137608 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor - Benzoimidazol-2-yl pyrimidines and pyrazines, pharmaceutical compositions and methods for H | 2009-05-28 |
20090137609 | VITAMIN D-LIKE COMPOUND - The present invention provides a compound represented by the following general formula (I): | 2009-05-28 |
20090137610 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS -
The invention provides compounds (Ia), (Ib) and (Ic), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families. | 2009-05-28 |
20090137611 | Fungicide N-Cyclopropyl-Sulfonylamide Derivatives - The present invention relates to N-cyclopropyl-sulfonylamide derivatives of formula (I) wherein the substituents are cyclic groups, their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions: (I) | 2009-05-28 |
20090137612 | Treatment with combined use of oxypurines and ascorbate to prevent and mitigate iron-catalized oxidative damage in Alzheimer's disease and other neurodegenerative disorders - A method is provided for the prevention and treatment of selective progressive degeneration within the central nervous system caused by hydroxyl-free or ferryl-free radicals formed by Fenton-type catalyzed reactions between diffusible hydrogen peroxide and localized bivalent iron. The invention embodies unique pharmacologic composition for antioxidant protection by oral supplementation with hypoxanthine conjointly with either sodium L-ascorbate or L-ascorbic acid. The hypoxanthine is provided for its sodium-dependent intestinal absorption and transport for the systemic production of higher antioxidant and iron-chelating uric acid levels. Ascorbate is provided as potent antioxidant to raise body ascorbic acid levels concurrently and to protect against possible deleterious effect from nucleobase or other molecular injury induced by oxidized uric acid as urate anion free radical caused in the antioxidant action of the uric acid. It is contemplated that such oral supplementation conjointly with hypoxanthine and L-ascorbate will support better health and will mitigate the progressive oxidative neuronal damage in Alzheimer's disease, amnestic mild cognitive impairment, Down syndrome, amyotrophic lateral sclerosis, and Parkinson's disease. | 2009-05-28 |
20090137613 | PHARMACEUTICALLY ACCEPTABLE SALTS AND POLYMORPHIC FORMS - The present invention is concerned with new pharmaceutically acceptable salts of valacyclovir, polymorphic forms, processes for preparing the new pharmaceutically acceptable salts and new polymorphic forms, pharmaceutical compositions containing the same, therapeutic uses thereof and methods of treatment employing the same. | 2009-05-28 |
20090137614 | Pharmaceutical combination comprising vitamin k - It is found that compounds having PPARδ agonistic activity induced abnormal blood coagulation or muscular disorder. A pharmaceutical combination comprising vitamin K and a compound having PPARδ agonistic activity can prevent the abnormal blood coagulation. A pharmaceutical composition comprising vitamin K can prevent muscular disorder. | 2009-05-28 |
20090137615 | INDAZOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOUR AGENTS - A quinazoline derivative of the Formula (I): wherein the substituents are as defined in the text for use in the production of an anti-proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man. | 2009-05-28 |
20090137616 | METHOD FOR THE CONTROL OF PHYTOPATHOGENIC FUNGI - The present invention provides a method of controlling | 2009-05-28 |
20090137617 | USE OF HAPTOGLOBIN GENOTYPING IN DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASE - This invention is directed to methods and compositions for the treatment of cardiovascular disorders. Specifically, the invention is directed to compositions comprising vitamin E, statins and/or glutathione peroxidase mimetics; methods of treating diabetic patients expressing the Hp-2-2 haptoglobin genotype; a method of inhibiting or suppressing a cardiovascular disorder in a diabetic subject, treating cardiovascular disease in subjects exhibiting the Haptoglobin Hp-2-2 genotype; and methods of treating cardiovascular disease in subjects exhibiting the Haptoglobin Hp-2-2 genotype. | 2009-05-28 |
20090137618 | PRO-DRUGS FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS - Pro-drugs containing an electron withdrawing substituent, as defined in the specification, are useful in a method for providing a patient with post administration-activated, controlled release of a biologically active compound. | 2009-05-28 |
20090137619 | Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent - A method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent of the family of platin compounds, taxanes, epothilone class, vinca alkaloids, said method comprising the administration in a co-ordinated manner to a subject suffering from said peripheral neuropathies, or expected to suffer from said peripheral neuropathies, an effective amount of acetyl L-carnitine or of a pharmaceutically acceptable salt thereof. In case of prevention, acetyl L-carnitine is administered to a subject, in view of the need of a treatment with an anticancer agent, immediately before or immediately after surgical removal of the tumor, but in any case before the administration of the anticancer agent. Acetyl L-carnitine can enhance the supportive effect of physiological NGF during chemotherapy-induced neuropathy, thus avoiding the problem of the local and general side effects of the exogenous administration of NGF which are a major problem of this neuroprotective strategy. | 2009-05-28 |
20090137620 | USE OF GALLIUM(III) COMPLEXES FOR THE TREATMENT OF MELANOMAS - The invention relates to the use of gallium (III) complexes for the treatment of melanomas. | 2009-05-28 |
20090137622 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS - There is provided the use of compounds of formula I | 2009-05-28 |
20090137623 | MUSCARINIC RECEPTOR ANTAGONISTS - The present invention relates to muscarinic receptor modulators, specifically, 7-oxo-2-azabicyclo[2.2.1]heptanes of formula (I) which are useful for the treatment of various diseases and conditions, for example, Alzheimer's disease, glaucoma, psychosis, particularly schizophrenia or schizophreniform conditions, mania, pain, bipolar disorder, depression, sleeping disorders, epilepsy, gastrointestinal motility disorders, urinary incontinence, and cognition enhancement. | 2009-05-28 |
20090137624 | Chemical Compounds - This invention relates to novel compounds having the formula (I): and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer. | 2009-05-28 |
20090137625 | Novel Enantiomers and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors - This invention relates to novel enantiomers useful as monoamine neurotransmitter re-uptake inhibitors. | 2009-05-28 |
20090137626 | Pharmaceutical Composition Containing PPARgamma Agonist - [Object] To provide a highly safe method for treating diabetes that demonstrates superior effects and is capable of inhibiting adverse side effects. | 2009-05-28 |
20090137627 | Method for Treating Chronic Pain - A method for the treatment of chronic pain in a mammal is provided. The method comprises administering to a mammal (e.g., a human) suffering from chronic pain a pain relieving amount of a diarylureido-dihalokynurenate compound. Preferred diarylureido-dihalokynurenate compounds are esters (e.g., ethyl esters). Particularly preferred are diphenylureido-dichlorokynurenate compounds. | 2009-05-28 |
20090137628 | Formulations of Indanylamines and the Use Thereof as Local Anesthetics and as Medication for Chronic Pain - Dermal and mucosal formulations of 2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine, characterized by rapid dermal and mucosal absorption and long duration of therapeutic activity are provided. Also provided are solutions of 2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine for injection, characterized by short onset time and long duration of activity. Formulations containing both 2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine and capsaicin are also provided. | 2009-05-28 |
20090137629 | Sigma receptor binding agent containing indanone derivative - A method for treatment of a mental disorder containing the step of administering a therapeutically effective amount of a sigma receptor binding agent containing an indanone compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. | 2009-05-28 |
20090137630 | SUBSTITUTED THIOPHENES: COMPOSITIONS, PROCESSES OF MAKING, AND USES IN DISEASE TREATMENT AND DIAGNOSIS - The present invention comprises compounds and compositions comprising substituted thiophene derivatives with the following backbone structure: | 2009-05-28 |
20090137631 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REGULATION OF G- AND/OR GC-RICH NUCLEIC ACID EXPRESSION - Methods and pharmaceutical compositions for regulations of Guanosine- (G-) and/or Guanosine-cytosine-rich (GC-rich) nucleic acid expressions are provided. The methods include a step of interacting the G- and/or GC-rich region of the nucleic acid with thalidomide, and the pharmaceutical compositions include the thalidomide and a pharmaceutical carrier. | 2009-05-28 |
20090137632 | Compositions And Methods For Treating Dyslipidemia - The present invention provides a method for treating dyslipidemia in a mammal, comprising administering to a mammal in need thereof, an effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt or solvate thereof and at least one statin. | 2009-05-28 |
20090137633 | Stable pharmaceutical composition of rabeprazole - The present invention relates to a method of preparing a stable pharmaceutical composition of rabeprazole. The preparation may be used as an injectable dosage form in the treatment of severe gastric ulcers. | 2009-05-28 |
20090137634 | Pest control agents - Disclosed is a composition for use as a pest control agent, comprising a compound represented by formula (I) or an agriculturally and horticulturally acceptable salt thereof as active ingredient and an agriculturally and horticulturally acceptable carrier: | 2009-05-28 |
20090137635 | DERIVATIVES OF 5-AMINO-4,6-DISUBSTITUTED INDOLE AND 5-AMINO-4,6-DISUBSTITUTED INDOLINE AS POTASSIUM CHANNEL MODULATORS - This invention provides compounds of formula I | 2009-05-28 |
20090137636 | Reverse Isoxazoles - The present invention relates to polycyclic compounds, processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them. | 2009-05-28 |
20090137637 | Tetrazolyl-Methylene Amino Acid Derivatives - This invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof; a pharmaceutical composition; a method of treating a disease mediated by an MMP-13 enzyme in a mammal; and a therapeutic combination containing at least two pharmaceutically active components, wherein R | 2009-05-28 |
20090137638 | Thiazolidinedione analogues - The present invention relates to thiazolidinedione analogues that are useful for treating hypertension. | 2009-05-28 |
20090137639 | METHODS FOR CONTROLLING FUNGI AND BACTERIA - The present invention includes compounds of pyridinium salts and methods of their use for agricultural purposes. The present invention also relates to methods of controlling fungi and/or bacteria. | 2009-05-28 |
20090137640 | POTENTIATOR FOR RADIATION THERAPY COMPRISING PYRIDINE DERIVATIVE AS ACTIVE INGREDIENT - The present invention relates to a radiotherapy enhancer that can reduce the radiation dose and adverse drug reactions when used in combination with a cancer radiotherapy. There is provided a radiotherapy enhancer comprising, as an active ingredient, a pyridine derivative represented by general formula (1): | 2009-05-28 |
20090137641 | Potassium Channel Activators for the Prevention and Treatment of Dystonia and Dystonia-Like Symptoms - The present invention is directed to the prevention, reversal and medical treatment of dystonia and dyskinesia as well as other diseases related to movement disorders, both in human beings and animals by administering a neuronal potassium channel opener such as flupirtine, retigabine or maxipost. | 2009-05-28 |
20090137642 | 2-Acylaminothiazole Derivatives - The Invention relates to compounds of the formula I, wherein the variables are as defined in the claims, for use as a medicament. The compounds are A | 2009-05-28 |
20090137643 | Methods for Inhibiting or Reversing Tau Filament Fibrillization - Methods for inhibiting and/or reversing tau filament formation or fibrillization are provided. These methods can be used for treating certain neurological disorders in vivo by administering pharmaceutical compositions which inhibit and/or reverse tau filament formation or fibrillization. A preferred composition comprises 3-(2-hydroxyethyl )-2-[2-[[3-(2-hydroxyethyl )-5-methoxy-2-benzothiazolylidene]methyl]-1-butenyl]-5-methoxybenzothiazolium. | 2009-05-28 |
20090137644 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS - This invention describes compounds and pharmaceutical compositions useful as inhibitors of ubiquitination. The compounds and compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. In particular, the compounds and compositions are useful for treating diseases caused by viruses such as poxviruses and retroviruses. The invention further provides for methods of treating smallpox, Herpes virus and HIV infection in patients using the compounds and compositions of the invention. | 2009-05-28 |
20090137645 | Shelf-Stable Famotidine Granulates for Oral Suspensions - A granulate for oral suspension that is particularly useful for the storage and reconstitution of famotidine into a liquid suspension. | 2009-05-28 |
20090137646 | 1,2 Benzoisothiazole Derivative, and Agricultural or Horticultural Plant Disease- Controlling Agent - A 1,2-benzoisothiazole derivative or a salt thereof is not harmful to a crop and is remarkably effective against agricultural or horticultural plant diseases such as | 2009-05-28 |
20090137647 | Modified Macrophage Migration Inhibitory Factor Inhibitors - Provided are various compounds of Formula I (I). Also provided are various compounds of Formula II (II). Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock. Also providcd are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor. | 2009-05-28 |
20090137648 | PROCESS FOR THE PREPARATION OF IRBESARTAN HYDROCHLORIDE - The present invention is concerned with a process for the preparation of 2n-butyl-4-spirocyclopentane-1-[(2′-(tetrazol-5-yl)biphenyl-4-yl)methyl]-2-imidazolin-5-one hydrochloride, irbesartan hydrochloride, novel hydrated and anhydrous crystalline forms thereof, amorphous irbesartan hydrochloride, formulations containing the same, therapeutic uses thereof and methods of treatment employing the same. The process of the present invention is a one-pot process which comprises reacting intermediate compounds 2n-butyl-1,3-diazaspiro[4,4]non-1-en-4-one and 5-(4′-bromomethyl-biphenyl-2-yl)-1-trityl-1H-tetrazole. | 2009-05-28 |
20090137649 | Concentrated liquid triazole-fungicide formulations - Concentrated liquid formulations of triazole fungicides are provided and the use of such formulations in diluted form for the control of harmful fungi. The formulations are both storage stable and prevent crystallization of the triazole fungicide when applied in diluted form. | 2009-05-28 |
20090137650 | New Compounds - The present invention relates to new compounds of formula I, | 2009-05-28 |
20090137651 | PHARMACEUTICAL COMPOSITION FOR EXTERNAL USE - A pharmaceutical composition for external use, including: i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and ii) one or two or more selected from N-methyl-2-pyrrolidone, propylene carbonate, and crotamiton. | 2009-05-28 |
20090137652 | METHODS FOR NEUROPROTECTION - This invention is directed to methods for providing neuroprotection comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II), or a pharmaceutically acceptable salt or ester thereof: | 2009-05-28 |
20090137653 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE - This invention is directed to substituted benzylamines which are useful as inhibitors of the CYP2A6 enzyme. Pharmaceutical compositions comprising the compounds and methods of using the compounds to treat nicotine dependence are also disclosed. | 2009-05-28 |
20090137654 | METHODS OF MODULATING BINDING OF SON OF SEVENLESS TO PHOSPHATIDIC ACID AND IDENTIFYING COMPOUNDS THAT MODULATE SUCH BINDING - The present invention relates to methods of modulating binding of Son of sevenless to phosphatidic acid and identifying compounds that modulate such binding. In particular, the present invention relates to a method of controlling pleckstrin homology domain-dependent membrane recruitment of Son of sevenless or histone folds domain-dependent membrane recruitment of Son of sevenless. Also disclosed are methods of controlling Ras and treating a subject for a condition mediated by Ras. The present invention also relates to a method of identifying compounds potentially effective in treating a condition mediated by Ras. | 2009-05-28 |
20090137655 | Non-Steroidal Ligands for the Glucocorticoid Receptor, Compositions and Uses Thereof - The invention provides non-steroidal ligands for the glucocorticoid receptor, methods for making non-steroidal ligands of the glucocorticoid receptor, compositions of non-steroidal ligands of the glucocorticoid receptor and methods of using non-steroidal ligands and compositions of non-steroidal ligands of the glucocorticoid receptor for treating or preventing diseases (e.g., obesity, diabetes, depression, neurodegeneration or an inflammatory disease) associated with glucocorticoid binding to the glucocorticoid receptor. | 2009-05-28 |
20090137656 | Intermolecular Association Complex of a Carrier and of an Active Principle - The invention relates to an intermolecular association complex of formula (I) of an amphiphilic carrier and of an active principle Z-Y, in which; S, X n, R | 2009-05-28 |
20090137657 | EXTERNAL LIQUID PREPARATION CONTAINING INDOMETHACIN - The present invention provides an indomethacin-containing external liquid preparation which provides good feeling of use, which exhibits high percutaneous absorption of indomethacin, and which, particularly in a low-temperature environment, does not cause precipitation of crystals with time. | 2009-05-28 |
20090137658 | BENZENESULFONIC ACID SALT COMPOUNDS - Besylate salts of trans-4-({2-[(2S)-2-cyano-pyrrolidinyl]-2-oxoethyl}amino)-N,N-dimethylcyclohexanecarboxamide are described as well as methods of using the same in the treatment of disorders characterized by hyperglycemia. | 2009-05-28 |
20090137659 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM - Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity. | 2009-05-28 |
20090137660 | Cytokine Modulators Using Cyclic Glycerides of Essential Polyunsaturated Fatty Acids - A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R | 2009-05-28 |
20090137661 | PLANT DERIVED COMPOUNDS AND COMPOUND FORMULAE CONTAINING THE SAME FOR THE TREATMENT OF CERVICAL CANCER - A composition for reducing the activity of a cervical cancer cell is provided. The composition includes at least one of the following compounds: isopsoralen, triptolide, baicalein, gallic acid, quercetin, gossypol-acetic acid, baicalin, berberine hydrochloride, and derivatives thereof in a sufficient amount to reduce the activity of the cervical cancer cell in the subject. | 2009-05-28 |
20090137662 | SYNERGY OF DOPAMINE D2 AND ADENOSINE A2 RECEPTORS ACTIVATES PKA SIGNALING VIA BETA/GAMMA DIMERS - This invention pertains to the discovery that a dopamine receptor agonist can activate PKA signaling and/or can act synergistically with an adenosine receptor to activate such signaling. In various embodiments, this invention exploits the synergy between the dopamine receptor pathway and an adenosine receptor pathway to provide methods of mitigating one or more symptoms produced by the chronic consumption of a substance of abuse or to mitigate one or more physiological and/or behavioral symptoms associated with cessation of chronic consumption of a substance of abuse. In certain embodiments, the methods involve administering to the mammal an effective amount of an adenosine receptor antagonist; and an effective amount of a dopamine receptor antagonist; where the effective amount of the adenosine receptor antagonist is lower than the effective amount of an adenosine receptor antagonist administered without said dopamine receptor antagonist. | 2009-05-28 |
20090137663 | Therapeutic micro nutrient composition for drug delivery - A lecithin based biphasic injection dosage formulation is disclosed which is applicable to subcutaneous, intramuscular, and intravenous administration. The formulation is characterized in that it comprises an adjustable buffer, an antoxidant, and a stabilizer. It is further characterized in that it includes liposomes, and that the components of these liposomes are therapeutic in the treatment of several human ailments. The formulation is characterized in that it comprises a carrier of biologically active substances. | 2009-05-28 |
20090137664 | SAURURUS CERNUUS COMPOUNDS THAT INHIBIT CELLULAR RESPONSES TO HYPOXIA - Compounds and compositions that effectively block hypoxia-inducible factor-1 function, and methods of use thereof. The compounds and compositions of the present invention are useful in the prevention and treatment of cancer, stroke, heart disease, ocular neovascular diseases, and arthritis. | 2009-05-28 |
20090137665 | NOVEL METHOD OF NEUROPROTECTION BY PHARMACOLOGICAL INHIBITION OF AMP-ACTIVATED PROTEIN KINASE - A method of neuroprotection which comprises administration of an AMPK inhibitor to a patient who is experiencing or has experienced a stroke, the compound being an AMPK inhibitor. Treatments with these agents significantly reduce the size of infarcts, and therefore minimize the loss of brain tissue and neurons. Thus, function can be preserved after stroke or ischemic injury in the brain. Similarly, neuronal loss can be minimized in degenerative diseases that cause neuronal compromise by perturbing energy utilization and availability in neurons. | 2009-05-28 |
20090137666 | FLUORESCENT PARTICLES COMPRISING NANOSCALE ZnO LAYER AND EXHIBITING CELL-SPECIFIC TOXICITY - Multifunctional “smart” nanostructures are disclosed that include fluorescein isothiocyanate (FITC)-encapsulated SiO | 2009-05-28 |
20090137667 | Pesticide Delivery System - An improved pesticide delivery system is disclosed. The system is based on a microblend comprising (a) an amphiphilic compound containing at least one hydrophilic group and at least one hydrophobic group and (b) a pesticide. Compositions based on the microblend and methods of using the compositions to control pests are also disclosed. | 2009-05-28 |
20090137668 | C-NITROSO-DERIVED NITROXYL DONORS - Active compounds of Formula (I) are described: wherein: R | 2009-05-28 |
20090137669 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS - The present invention provides a creatine ester anti-inflammatory compound which may be received by animals and then metabolized into a biologically active form of creatine. The biologically active creatine inhibits the production of chemical mediators, released during an inflammatory response, which are important components in the inflammatory response and the inflammation and pain resulting from physical or chemical trauma to cells and tissue. | 2009-05-28 |
20090137670 | Amino Acid Compounds - Carnitine and Taurine Compounds are described. The Carnitine Compound comprises Carnitine and one of a Nitrate and a Nitrite. The Taurine Compound comprises Taurine and one of a Nitrate and a Nitrite. | 2009-05-28 |
20090137671 | METHODS OF TREATING METABOLIC DISORDERS - A method of increasing the insulin sensitivity of insulin resistant cells includes administering to the cells an amount of all-trans-retinoic acid effective to activate transcription factor perosixome proliferator-activated receptor (PPAR) β/δ of the cells. | 2009-05-28 |
20090137678 | HIGH YIELD SYNTHESIS METHODS FOR PRODUCING ORGANIC SALTS OF STRONTIUM - New organic salts of strontium and methods of synthesizing such salts with high purity, high yields and with short processing times, at neutral conditions and at low reaction temperature, such as a temperature at or below 50° C. | 2009-05-28 |
20090137679 | ZN2+Chelating Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors | 2009-05-28 |
20090137680 | NOVEL NON-SELECTIVE CATION CHANNEL IN NEURONAL CELLS AND METHOD FOR TREATING BRAIN SWELLING - The present invention is directed to therapeutic compounds, treatment methods, and kits affecting the NC | 2009-05-28 |
20090137681 | Sirtuin Inhibiting Compounds - Provided herein are compositions and methods for treating or preventing cancer and autoimmune diseases. Compositions comprise a sirtuin inhibitory compound that decreases the activity of a sirtuin, such as SIRT1 or Sir2. Exemplary methods comprise contacting a cell or a molecule with a sirtuin inhibitory compound that decreases the activity of a sirtuin and thereby reduces the life span of a cell, kills the cell or renders it susceptible to certain cell stresses including radiation and chemotherapy. Other methods include treating pathogens expressing a sirtuin. | 2009-05-28 |
20090137682 | Combination cancer therapy with bis(thiohydrazide) amide compounds - A method of treating a subject with cancer includes the step of co-administering to the subject over three to five weeks, a taxane in an amount of between about 243 μmol/m2 to 315 μmol/m2 (e.g., equivalent to paclitaxel in about 210-270 mg/m2); and a bis(thiohydrazide amide) in an amount between about 1473 μmol/m2 and about 1722 μmol/m2 (e.g., Compound (1) in about 590-690 mg/m2). The bis(thiohydrazide amide) is represented by Structural Formula (I), Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group. R | 2009-05-28 |
20090137683 | Anticancer effect enhancer - An object of the present invention is to provide an enhancing agent for effect of anticancer agent for achieving an excellent therapeutic effect on cancer. The enhancing agent for effect of anticancer agent according to the present invention which is a solving means therefor is characterized in that a nitric oxide donor is an effective ingredient. In accordance with the present invention, an excellent therapeutic effect is able to be achieved on non-small cell lung cancer which is still in such a state that no effective therapeutic method has been established yet for a progressive cancer which is not operable and is one of cancers where chemotherapy is most difficult to apply. | 2009-05-28 |
20090137684 | SUSTAINED-RELEASE PREPARATIONS AND METHOD FOR PRODUCING THE SAME - The present invention relates to sustained-release preparations prepared by double granulation and methods for producing the same. The sustained-release preparations according to the present invention enables maintenance of effective blood concentration of drug for many hours via sustained release of the drug over 12 hours or more, and further its production is easy owing to convenience of process. | 2009-05-28 |
20090137685 | Therapeutic Agent for Inflammatory Bowel Disease Containing as Active Ingredient 2-Amino-1,3-Propanediol Derivative, or Method for Treating Inflammatory Bowel Disease - A novel therapeutic and prophylactic agent for inflammatory bowel diseases and a method for treating inflammatory bowel diseases. | 2009-05-28 |
20090137686 | Treatment of Ophthalmic Diseases - Beta-amino alcohols are useful for the treatment of ophthalmic conditions. | 2009-05-28 |
20090137687 | Compositions and Methods With Enhanced Therapeutic Activity - This invention relates to novel tricyclic quinone and catechol compositions, compositions containing prodrugs of tricyclic quinone and catechol compositions, and methods of use for the treatment of solid tumor cancers and other vascular proliferative disorders. In certain aspects, the compositions of the invention are capable of generating both a vascular targeting effect and tumor cell cytotoxicity (e.g., by oxidative stress) in order to achieve an enhanced anti-tumor response in a patient. | 2009-05-28 |
20090137688 | PHARMACEUTICAL PRODUCT - The present invention relates to a pharmaceutical product comprising porous silicon, a beneficial substance, and an excipient, the beneficial substance being located in at least some of the pores of the porous silicon, and the excipient having a structure and composition such that it has a melting point between 25 C and 45 C. The invention allows improved control over the release of a beneficial substance from porous silicon. | 2009-05-28 |
20090137689 | Modified gum arabic - The present invention provides a water-soluble modified gum arabic with a weight average molecular weight not less than 0.9 million and arabinogalactan protein not less than 17% by weight obtained by heating | 2009-05-28 |
20090137690 | Delinked Polymer Modified Bitumen and Method of Producing Same - A delinked polymer modified bitumen comprising a delinked polymer-bitumen composite and additional bituminous material. The delinked polymer-bitumen composite comprises sulfur-cured elastomeric material having a vulcanized network and a plurality of polymer backbones; at least one rubber accelerator and at least one activator in sufficient quantities to delink the vulcanized network of the sulfur-cured elastomeric material; and at least one bituminous material, where the sulfur-cured elastomeric material, the rubber accelerator, the activator, and the bituminous material are mixed under high shear conditions at a temperature greater than 70° C. to produce the delinked polymer-bitumen composite. | 2009-05-28 |
20090137691 | Thermally Foamable Microsphere, Production Process Thereof, and Composition - A thermally foamable microsphere having a structure that a foaming agent is encapsulated in an outer shell formed from a polymer, wherein supposing an electric conductivity of a water extract obtained by Step 1 of dispersing 5 g of the thermally foamable microsphere in 20 g of ion-exchanged water having a pH of 7 and an electric conductivity of σ1 at a temperature of 25° C. to prepare a liquid dispersion; and Step 2 of shaking the liquid dispersion at the same temperature for 30 minutes to conduct a water extraction treatment, as measured at 25° C. is σ2, a difference σ2−σ1 between σ2 and σ1 is at most 1 mS/cm, and a production process including measuring an electric conductivity of a filtrate in the washing step to obtain a thermally foamable microsphere exhibiting a desired electric conductivity on the basis of a previously prepared relational expression between the electric conductivity of the filtrate and the electric conductivity of a water extract of the thermally foamable microsphere. | 2009-05-28 |
20090137692 | PRODUCTION METHOD OF POROUS RESIN PARTICLE HAVING HYDROXYL GROUP - The present invention relates to a method for producing a porous resin particle containing an aromatic vinyl compound-aromatic divinyl compound copolymer having a hydroxyl group, the method including: dissolving a monomer mixture containing an aromatic vinyl compound, an aromatic divinyl compound and a (meth)acrylic acid ester having one hydroxyl group within the molecule thereof, and a polymerization initiator in an organic solvent to obtain a solution containing the monomer mixture and the polymerization initiator; suspending the solution in water in the presence of a dispersion stabilizer; and performing a suspension copolymerization. The method of the invention is capable of easily producing a porous resin particle containing an aromatic vinyl compound-aromatic divinyl compound copolymer having a hydroxyl group, that is used as a support for solid phase synthesis and enables efficient nucleic acid synthesis. | 2009-05-28 |
20090137693 | High Strength Monolithic Carbon Foam - A carbon foam article useful for, inter alia, composite tooling or other high temperature applications, which includes a carbon foam having a ratio of compressive strength to density of at least about 7000 psi/g/cc. | 2009-05-28 |
20090137694 | METHOD OF SURFACE CROSS-LINKING SUPERABSORBENT POLYMER PARTICLES USING ULTRAVIOLET RADIATION - The present invention relates to a method of surface cross-linking superabsorbent polymer particles using UV irradiation. The method is carried out in a so-called drum reactor, which comprises a hollow drum and an irradiation source. The drum has a longitudinal axis and a cross-section. Radical former molecules are applied on the surface of superabsorbent polymer particles. These superabsorbent polymer particles are fed into the drum and are irradiated while they move within the drum, which is rotated around its longitudinal axis. The irradiation source is provided such that the radiation emitted by the irradiation source is able to reach superabsorbent polymer particles within said drum. The irradiation source for use in the method of the present invention is able to emit UV radiation of a wavelength between 201 nm and 400 nm. | 2009-05-28 |
20090137695 | Active Ray Curable Ink-Jet Ink - An active ray curable ink-jet ink comprising at least an organic pigment, a polymer dispersant, a photo-initiator and a cationic polymerizable compound, wherein the active ray curable ink-jet ink incorporates a quaternary ammonium salt and a content of the quaternary ammonium salt is not less than 5 ppm and not more than 500 ppm. | 2009-05-28 |
20090137696 | METHOD FOR STABILIZING REFRACTIVE INDEX PROFILES USING POLYMER MIXTURES - A method for making an optical element comprises polymerizing a first monomer to form a first polymer, the first polymer having a spatially varying degree of cure that provides a predetermined refractive index profile; and polymerizing a second monomer in the presence of the first polymer to form a second polymer intermixed with the first polymer, the second polymer stabilizing the first polymer and the refractive index profile. | 2009-05-28 |
20090137697 | Dental Curable Composition and Kit for Such Dental Curable Composition - A dental curable composition has a curing time of 30 seconds to 120 minutes and includes a compound having an acidic group in the molecule (A), a polymerizable monomer (B), an organic amine compound (C) and a sulfur-containing reducing compound (D). In the dental curable composition, the content of the component (A) is 0.01 to 80 parts by weight, the content of the component (B) is 21 to 99.8 parts by weight, the content of the component (C) is 0.01 to 30 parts by weight and the content of the component (D) is 0 to 30 parts by weight. The composition may be cured at a relatively low temperature close to the body temperature without using a peroxide-based polymerization initiator, and has good sealing properties and adhesion. | 2009-05-28 |
20090137698 | AQUEOUS SILICONE DISPERSIONS, FORMULATIONS, ESPECIALLY PAINT FORMULATIONS, CONTAINING THEM AND ONE OF THEIR METHODS OF PREPARATION - The invention relates to an aqueous silicone dispersion, containing one or more polyorganosiloxanes (POSs) intended to be crosslinked or having been crosslinked by elimination of water or alcohol, according to a polycondensation mechanism. The present invention also relates to methods for preparing aqueous silicone emulsions and dispersions. | 2009-05-28 |
20090137699 | Stabilization of polyol or polyurethane compostions against thermal oxidation - The present invention pertains to compositions comprising a polyester polyol, a polyether polyol, an acrylic polyol, a polycarbonate polyol, a polybutadiene polyol, a hydrogenated polybutadiene polyol, a functionalized polyether and/or a polyurethane susceptible to thermal degradation, and at least one antioxidant of formula (101) and/or (102) and optionally further antioxidants. The present invention also pertains to the use of such stabilizer (blends) in said polyols, functionalized polyether and/or polyurethane against thermal degradation and a process for stabilizing said polyols, functionalized polyether and/or polyurethane with such stabilizer (blends) against thermal degradation | 2009-05-28 |
20090137700 | LOW COST, LOW-DENSITY, ABLATIVE RUBBER INSULATION FOR ROCKET MOTORS - An insulation material comprising a low-density EPDM polymer, at least one flame-retardant, and an organic filler. The insulation material is used in an insulation layer of a rocket motor. The organic filler is a polymeric, organic filler such as polyvinyl chloride. A rocket motor comprising an insulation material is also disclosed. The insulation material comprises a low-density EPDM polymer, at least one flame-retardant, and a polymeric, organic filler and is applied between an inner surface of a case of the rocket motor and a propellant. A method of insulating a rocket motor is also disclosed. | 2009-05-28 |
20090137701 | Pneumatic Tire - A pneumatic tire having excellent balance between low fuel consumption and grip property and capability of suppressing crack generation in a tread groove bottom while maintaining abrasion resistance is provided. The pneumatic tire has a tread formed from a rubber composition includes per 100 parts by weight of a diene rubber containing a styrene-butadiene rubber, from 30 to 150 parts by weight of a reinforcing filler containing from 20 to 100 parts by weight of silica, and from 5 to 40 parts by weight of a carboxyl-terminally modified liquid polybutadiene, and further includes a silane coupling agent in an amount of from to 25 parts by weight per 100 parts by weight of the silica. | 2009-05-28 |